Two Sigma Securities LLC Makes New $37,000 Investment in Galectin Therapeutics Inc. (NASDAQ:GALT)

Two Sigma Securities LLC purchased a new stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 28,571 shares of the company’s stock, valued at approximately $37,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GALT. Geode Capital Management LLC increased its holdings in Galectin Therapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 870,589 shares of the company’s stock worth $1,124,000 after acquiring an additional 8,047 shares during the period. Bank of New York Mellon Corp raised its position in shares of Galectin Therapeutics by 19.0% in the fourth quarter. Bank of New York Mellon Corp now owns 50,826 shares of the company’s stock worth $66,000 after buying an additional 8,105 shares in the last quarter. Inspire Advisors LLC boosted its stake in Galectin Therapeutics by 86.3% during the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company’s stock valued at $27,000 after buying an additional 9,772 shares during the period. Stratos Wealth Partners LTD. grew its position in Galectin Therapeutics by 27.4% during the fourth quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company’s stock worth $66,000 after buying an additional 11,100 shares in the last quarter. Finally, Traynor Capital Management Inc. increased its stake in Galectin Therapeutics by 29.9% in the 4th quarter. Traynor Capital Management Inc. now owns 55,670 shares of the company’s stock worth $72,000 after acquiring an additional 12,799 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a research note on Wednesday, April 2nd.

Galectin Therapeutics Stock Up 6.9 %

Shares of GALT stock opened at $1.39 on Friday. The business has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $1.73. Galectin Therapeutics Inc. has a 12-month low of $0.73 and a 12-month high of $3.59. The firm has a market cap of $87.82 million, a P/E ratio of -1.90 and a beta of 0.79.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, research analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.